糖尿病合并肌少症患者治疗研究进展

王 琪1, 王 君*2
1、承德医学院
2、保定市第一中心医院

摘要


糖尿病患者持续的高血糖状态可能导致微血管及大血管的并发症，近年来研究表明，肌肉减少症成为糖尿病患者的第三类并发症，肌肉减少症受到临床的关注，及早发现并积极干预可改善糖尿病合并肌少症患者的生活质量，本文就营养、运动及药物治疗等方面进行综述。

关键词


糖尿病；肌少症；治疗策略

全文:

PDF


参考


[1]Chen L K, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment[J]. Journal of the American Medical Directors Association, 2020, 21(3): 300-307.e2.

[2]Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Research and Clinical Practice, 2019, 157: 107843.

[3]Wang Y, Zhang Y, Lane N E, et al. Population‐based metagenomics analysis reveals altered gut microbiome in sarcopenia: data from the Xiangya Sarcopenia Study[J]. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13(5): 2340-2351.

[4]Izzo A, Massimino E, Riccardi G, et al. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors[J]. Nutrients, 2021, 13(1): 183.

[5]Hashimoto Y, Takahashi F, Okamura T, et al. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes[J]. Metabolism: Clinical and Experimental, 2023, 144: 155585.

[6]马懿真，杨丽娜.糖尿病性肌少症的实验研究进展[J].中国糖尿病杂志，2024，32（3）：231-234.

[7]徐成澜，刘炳丽，蒋兰兰，等.2型糖尿病合并肌少症的研究进展[J].中国糖尿病杂志，2024，32（10）：782-784.

[8]Chen H, Huang X, Dong M, et al. The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy[J]. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2023, 16: 1541-1554.

[9]Wang Y, Nie J, Ferrari G, et al. Association of Physical Activity Intensity With Mortality: A National Cohort Study of 403 681 US Adults[J]. JAMA Internal Medicine, 2021, 181(2): 203.

[10]Campos J C, Marchesi Bozi L H, Krum B, et al. Exercise preserves physical fitness during aging through AMPK and mitochondrial dynamics[J]. Proceedings of the National Academy of Sciences of the United States of America, 120(2): e2204750120.

[11]Dent E, Morley J E, Cruz-Jentoft A J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management[J]. The Journal of Nutrition, Health & Aging, 2018, 22(10): 1148-1161.

[12]Hurst C, Robinson S M, Witham M D, et al. Resistance exercise as a treatment for sarcopenia: prescription and delivery[J]. Age and Ageing, 2022, 51(2): afac003.

[13]Otsuka Y, Yamada Y, Maeda A, et al. Effects of resistance training intensity on muscle quantity/quality in middle‐aged and older people: a randomized controlled trial[J]. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13(2): 894-908.

[14]Chien Y H, Tsai C J, Wang D C, et al. Effects of 12-Week Progressive Sandbag Exercise Training on Glycemic Control and Muscle Strength in Patients with Type 2 Diabetes Mellitus Combined with Possible Sarcopenia[J]. International Journal of Environmental Research and Public Health, 2022, 19(22): 15009.

[15]Kobayashi Y, Long J, Dan S, et al. Strength training is more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes: a randomised controlled trial[J]. Diabetologia, 2023, 66(10): 1897-1907.

[16]中华医学会老年医学分会，国家老年疾病临床医学研究中心（湘雅医院）.中国肌肉减少症诊疗指南（2024版）[J].中华医学杂志，2025，105（3）：181-203.

[17]Rogeri P S, Zanella R, Martins G L, et al. Strategies to Prevent Sarcopenia in the Aging Process: Role of Protein Intake and Exercise[J]. Nutrients, 2021, 14(1): 52.

[18]崔华，王朝晖，吴剑卿，等.老年人肌少症防控干预中国专家共识（2023）[J].中华老年医学杂志，2023，42（2）：144-153.

[19]Manders R J, Little J P, Forbes S C, et al. Insulinotropic and Muscle Protein Synthetic Effects of Branched-Chain Amino Acids: Potential Therapy for Type 2 Diabetes and Sarcopenia[J]. Nutrients, 2012, 4(11): 1664-1678.

[20]Agoncillo M, Yu J, Gunton J E. The Role of Vitamin D in Skeletal Muscle Repair and Regeneration in Animal Models and Humans: A Systematic Review[J]. Nutrients, 2023, 15(20): 4377.

[21]Ferrari U, Then C, Rottenkolber M, et al. Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study[J]. Acta Diabetologica, 2020, 57(9): 1057-1063.

[22]Xiang J, Qin L, Zhong J, et al. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway[J]. Diabetes, Metabolic Syndrome and Obesity, 2023, Volume 16: 2433-2446.

[23]Zhu G Z, Zhao K, Li H Z, et al. Melatonin ameliorates age-related sarcopenia by inhibiting fibrogenic conversion of satellite cell[J]. Molecular Medicine (Cambridge, Mass.), 2024, 30(1): 238.

[24]Reza M M, Subramaniyam N, Sim C M, et al. Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy[J]. Nature Communications, 2017, 8(1): 1104.

[25]Guo M, Yao J, Li J, et al. Irisin ameliorates age‐associated sarcopenia and metabolic dysfunction[J]. Journal of Cachexia, Sarcopenia and Muscle, 2022, 14(1): 391-405.


Refbacks

  • 当前没有refback。